The Importance of Timeliness in Outbreak Response: Introducing the WHO’s Early Action Review

By Staff Writer

September 5, 2023

The recent outbreaks of epidemic and pandemic-prone diseases have underscored the importance of timely and effective systems for outbreak detection, notification, and response. Early detection and response are crucial in preventing the escalation of outbreaks of infectious disease. To enhance the identification and control of these threats, ambitious and achievable targets are required.

In response to this need, the World Health Organization (WHO) has developed the Early Action Review (EAR), a performance improvement approach used to evaluate the timeliness of early detection activities and responses to any health event. The EAR, when repeated consistently, establishes the habit of ensuring continual learning and improvement from every event.

EAR is not just an assessment or monitoring tool: it’s a performance management process conducted as early as possible while an event is unfolding. It is used by teams responsible for responding to the event to reinforce the implementation of seven early response actions. These include initiating investigations, conducting epidemiologic analysis, obtaining laboratory confirmation, initiating appropriate case management and infection prevention measures, and establishing a coordination mechanism.


EAR also promotes collaboration and coordination among key stakeholders during the early outbreak response, increasing the likelihood of effective control. When a new outbreak or public health event is identified, stakeholders must coordinate efforts to control the spread of disease and reduce risks or impacts.

The EAR process is designed to find system bottlenecks and fix them quickly. Stakeholders in a response capture data about the timeliness and completion of early response actions as the event unfolds and then identify bottlenecks in the system and enablers of implementation. Documenting these bottlenecks and enablers is critical for prioritising immediate or longer-term remedial actions and identifying best practices.

The WHO has made available five tools to support the conduct of an EAR, which can be downloaded from their website. These tools will be periodically updated, as required. By implementing and improving the EAR process, countries can enhance both their detection speed and response quality, ultimately saving lives and preventing the spread of infectious diseases. 

Reference url

Recent Posts

oral cancer East Africa
   

Oral Cancer in East Africa: The Need for Early Detection

💡 Did you know that Toombak use is a leading risk factor for oral cancer in East Africa?

A recent scoping review sheds light on the shocking prevalence of oral cancer in the region, emphasising the urgent need for public health interventions and improved early detection strategies. Enhancing awareness around risk factors like Toombak, tobacco, and alcohol for tackling this growing health crisis.

Curious about the key insights and their implications for health economics? Look into the full article to find out more!

#SyenzaNews #HealthEconomics #Oncology #GlobalHealth

Novartis patent cliff layoffs
     

Engineering Resilience: Mastering Pharma Patent Expiration Strategy

🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?

Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.

#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.